Institute of Pharmaceutical Chemistry, ZAFES/LiFF/OSF Goethe-University Frankfurt, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1969-75. doi: 10.1016/j.bmcl.2012.01.038. Epub 2012 Jan 24.
A novel class of 5-lipoxygenase (5-LO) inhibitors characterized by a central imidazo[1,2-a]pyridine scaffold, a cyclohexyl moiety and an aromatic system, is presented. This scaffold was identified in a virtual screening study and exhibits promising inhibitory potential on the 5-LO. Here, we investigate the structure-activity relationships of this compound class. With N-cyclohexyl-6-methyl-2-(4-morpholinophenyl)imidazo[1,2-a]pyridine-3-amine (14), we identified a potent 5-LO inhibitor (IC(50)=0.16μM (intact cells) and 0.1μM (cell-free)), which may possess potential as an effective lead compound intervening with inflammatory diseases and certain types of cancer.
呈现了一类新型的 5-脂氧合酶(5-LO)抑制剂,其特征为一个中央咪唑并[1,2-a]吡啶骨架、一个环己基部分和一个芳香系统。这个支架是在虚拟筛选研究中确定的,对 5-LO 表现出有希望的抑制潜力。在这里,我们研究了这个化合物类别的构效关系。我们用 N-环己基-6-甲基-2-(4-吗啉基苯基)咪唑并[1,2-a]吡啶-3-胺(14)鉴定了一种有效的 5-LO 抑制剂(IC50=0.16μM(完整细胞)和 0.1μM(无细胞)),它可能作为一种有效的先导化合物,干预炎症性疾病和某些类型的癌症。